Sanifit Therapeutics, S.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sanifit Therapeutics, S.A. - overview
Established
2007
Location
Palma, -, Spain
Primary Industry
Pharmaceuticals
About
Based in Palma de Mallorca, Spain, and founded in 2007 by Joan Perello, Laboratoris Sanifit, S. L. is a clinical-stage biopharmaceutical company that treats vascular calcification disorders. In June 2019, Laboratoris Sanifit, S.
L. raised EUR 17 million in venture debt financing from unspecified investors. The company has raised a total of USD 128. 31 million in funding and Joan Perello is the CEO.
Sanifit Therapeutics, S. A. is developing SNF472, which is a small molecule that is a selective and potent inhibitor of hydroxyapatite (HAP) crystallization that treats calciphylaxis or CUA (calcific uremic arteriolopathy) for patients undergoing dialysis. As of December 2021, SNF472 is under phase 3 clinical development.
Sanifit Therapeutics, S. A. has generated USD 0. 002 million in revenue in the fiscal year ended in December 2019.
Current Investors
La Caixa Group, Riva y Garcia Private Equity, Caixa Capital Risc
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.sanifit.com
Total Amount Raised
Subscriber access only
Sanifit Therapeutics, S.A. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 141,088.7 | 711.7 | 31,547.9 | 31,792.8 | 2,053.2 | 2,536.3 | - | - | - |
| % Revenue Growth (YoY) | - | (99.5%) | 4332.8% | 0.8% | (93.5%) | 23.5% | - | - | - |
| EBITDA (USD) | (4,279,629) | (8,350,850.3) | (16,145,698.4) | (21,375,678) | (17,478,641.6) | (18,488,767.2) | - | - | - |
| Operating Income (USD) | (5,133,925.6) | (8,372,841.8) | (16,167,616.2) | (21,395,107.3) | (17,516,524.7) | (18,526,302) | - | - | - |
| Operating Margin | (3638.8%) | (1176456.6%) | (51247.8%) | (67295.4%) | (853132.9%) | (730446.0%) | - | - | - |
| % EBITDA Margin | (3033.3%) | (1173366.6%) | (51178.4%) | (67234.3%) | (851287.8%) | (728966.1%) | - | - | - |
| NET Income (USD) | (5,585,759.7) | (8,294,520.8) | (16,311,119.7) | (24,522,823.5) | (15,686,164.2) | (17,210,359.6) | - | - | - |
| % Net Margin | (3959.0%) | (1165451.8%) | (51702.7%) | (77133.3%) | (763986.2%) | (678561.7%) | - | - | - |
Sanifit Therapeutics, S.A. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member Board Of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.